While news reports highlight a slowdown in tech funding relative to 2020-2021 (NYT here today), many sciences of vibrant progress in fields like the genomics of minimal residual disease detection.
In one press release, Adaptive Biotechnologies highlights more than 30 abstracts on ClonoSEQ and MDR testing at the current ASH conference in the heme-onc field.
Read more here:
